COPD
GOLD 2026 (Global Initiative for Chronic Obstructive Lung Disease) is the reference strategy, updated each year. This summary follows the 2026 Pocket Guide.
What's new
- Group E now starts at one moderate or severe exacerbation in the past year.
- CAT renamed CAAT (Chronic Airways Assessment Test).
- Biologics for exacerbations with eosinophils ≥300 despite triple therapy: dupilumab (with chronic bronchitis) and mepolizumab.
- Ensifentrine as an add-on for persistent dyspnoea.
- RSV vaccine for people with COPD.